Sugi Predict

Sugi Predict / Targets / SPPL2B

SPPL2B

Signal peptide peptidase-like 2B · Q8TCT7 · SPPL2B on Sugi Atlas →

71 patent compounds predicted against SPPL2B, 36 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL31458868 SCHEMBL31458868 1.00 1/20
SCHEMBL31654095 SCHEMBL31654095 1.00 1/20
SCHEMBL26848272 SCHEMBL26848272 0.66 1/20
SCHEMBL26848251 SCHEMBL26848251 0.62 1/20
SCHEMBL26848295 SCHEMBL26848295 0.60 1/20
SCHEMBL26848298 SCHEMBL26848298 0.59 1/20
SCHEMBL30617042 SCHEMBL30617042 0.59 1/20
SCHEMBL12061629 SCHEMBL12061629 0.51 1/20
SCHEMBL12061807 SCHEMBL12061807 0.51 1/20
SCHEMBL25409439 SCHEMBL25409439 0.51 1/20
SCHEMBL26848296 SCHEMBL26848296 0.47 1/20
SCHEMBL26848301 SCHEMBL26848301 0.47 1/20
SCHEMBL30617020 SCHEMBL30617020 0.47 1/20
SCHEMBL30617038 SCHEMBL30617038 0.47 1/20
SCHEMBL28738351 SCHEMBL28738351 0.46 1/20
SCHEMBL28738352 SCHEMBL28738352 0.46 1/20
SCHEMBL1040532 SCHEMBL1040532 0.45 1/20
SCHEMBL1682315 SCHEMBL1682315 0.44 1/20
SCHEMBL25410949 SCHEMBL25410949 0.43 1/20
SCHEMBL25410953 SCHEMBL25410953 0.43 1/20

Clinical trials — most relevant to SPPL2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients PHASE3UNKNOWN
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers PHASE2COMPLETED
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients PHASE2RECRUITING
Pappalysin 2 (PAPP-A2) Enzyme Replacement PHASE1COMPLETED
PTHrP(1-36) IV Dose Escalation Study PHASE1WITHDRAWN
Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI EARLY_PHASE1RECRUITING
Surfactant Derived Protocol in Heart Failure nanCOMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Urine and Serum Concentrations of Pregnancy-Associated Compounds During Gestation nanCOMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Novel Biomarkers of Preeclampsia, Aquaporin, Fatty Acid, and S110B nanCOMPLETED
Catalytic Antibodies to Predict Uninvasively Late Transplant Failure nanCOMPLETED
Biomarkers of Lichen Sclerosus nanUNKNOWN
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings nanUNKNOWN
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy nanCOMPLETED
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism nanUNKNOWN
Analysis by Clinical Mass Spectrometry of Bloodstains nanCOMPLETED
Proteomic Study of Urinary Stone Disease nanCOMPLETED
The Recurrence Study nanUNKNOWN
Predictive Value of Osteopontin for Contrast Nephropathy nanUNKNOWN
Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction nanRECRUITING
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin nanCOMPLETED
Factors Involved in Asthma and Airway Inflammation nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence nanWITHDRAWN
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Discovery of New Circulating Biomarkers of Coronary Atherosclerosis nanCOMPLETED
Identification of Biomarkers for Early Detection of Pancreatic Cancer nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SPPL2B binder may also engage these)

ProteinNameSimilarity
Q3TD49 — 0.996 Q3TD49 →
Q5PQL3 — 0.996 Q5PQL3 →
Q5F383 — 0.983 Q5F383 →
P97260 — 0.973 P97260 →
A2RRU4 — 0.972 A2RRU4 →
A6QM06 — 0.971 A6QM06 →
Q12770 — 0.970 Q12770 →
Q5MNU5 — 0.970 Q5MNU5 →
Q6GQT6 — 0.969 Q6GQT6 →
Q8MIQ9 — 0.967 Q8MIQ9 →
Q04671 — 0.966 Q04671 →
A6NDV4 — 0.966 A6NDV4 →
Q7Z403 — 0.965 Q7Z403 →
B1AWJ5 — 0.965 B1AWJ5 →
Q920N2 — 0.964 Q920N2 →
Q9R283 — 0.964 Q9R283 →
A6QLK4 — 0.963 A6QLK4 →
P56726 — 0.963 P56726 →
Q9JJH7 — 0.962 Q9JJH7 →
P97698 — 0.962 P97698 →
Q5GH56 — 0.962 Q5GH56 →
Q5GH73 — 0.962 Q5GH73 →
E1BBQ2 — 0.962 E1BBQ2 →
Q49LS8 — 0.961 Q49LS8 →
LPCAT1 Lysophosphatidylcholine acyltransferase 1 0.961 landscape →
Q496Y0 — 0.960 Q496Y0 →
SMO Protein smoothened 0.960 landscape →
Q6ZRP7 — 0.960 Q6ZRP7 →
Q9JI99 — 0.960 Q9JI99 →
TRPM4 Transient receptor potential cation channel subfamily M member 4 0.960 landscape →